Biodegradation of Diclofenac by the bacterial strain Labrys portucalensis F11 (cas 19340-14-8)
-
Add time:08/03/2019 Source:sciencedirect.com
Diclofenac (DCF) is a widely used non-steroidal anti-inflammatory pharmaceutical which is detected in the environment at concentrations which can pose a threat to living organisms. In this study, biodegradation of DCF was assessed using the bacterial strain Labrys portucalensis F11. Biotransformation of 70% of DCF (1.7–34 μM), supplied as the sole carbon source, was achieved in 30 days. Complete degradation was reached via co-metabolism with acetate, over a period of 6 days for 1.7 µM and 25 days for 34 μM of DCF. The detection and identification of biodegradation intermediates was performed by UPLC-QTOF/MS/MS. The chemical structure of 12 metabolites is proposed. DCF degradation by strain F11 proceeds mainly by hydroxylation reactions; the formation of benzoquinone imine species seems to be a central step in the degradation pathway. Moreover, this is the first report that identified conjugated metabolites, resulting from sulfation reactions of DCF by bacteria. Stoichiometric liberation of chlorine and no detection of metabolites at the end of the experiments are strong indications of complete degradation of DCF by strain F11. To the best of our knowledge this is the first report that points to complete degradation of DCF by a single bacterial strain isolated from the environment.
We also recommend Trading Suppliers and Manufacturers of F11 (cas 19340-14-8). Pls Click Website Link as below: cas 19340-14-8 suppliers
Prev:Carbamazepine is degraded by the bacterial strain Labrys portucalensis F11 (cas 19340-14-8)
Next:Supramolecular host-guest interactions of pseudoginsenoside F11 (cas 19340-14-8) with β- and γ-cyclodextrin: Spectroscopic/spectrometric and computational studies) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Assessing the stoichiometric efficacy of mammalian expressed paraoxonase-1 variant I-F11 (cas 19340-14-8) to afford protection against G-type nerve agents08/10/2019
- Humanization of JAA-F11 (cas 19340-14-8), a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis08/09/2019
- Pseudoginsenoside-F11 (cas 19340-14-8) alleviates cognitive deficits and Alzheimer’s disease-type pathologies in SAMP8 mice08/08/2019
- Enantioselective degradation of ofloxacin and levofloxacin by the bacterial strains Labrys portucalensis F11 (cas 19340-14-8) and Rhodococcus sp. FP108/07/2019
- Preclinical Analysis of JAA-F11 (cas 19340-14-8), a Specific Anti–Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging08/06/2019
- Pseudoginsenoside-F11 (cas 19340-14-8) Protects against Transient Cerebral Ischemia Injury in Rats Involving Repressing Calcium Overload08/05/2019
- Supramolecular host-guest interactions of pseudoginsenoside F11 (cas 19340-14-8) with β- and γ-cyclodextrin: Spectroscopic/spectrometric and computational studies08/04/2019
- Carbamazepine is degraded by the bacterial strain Labrys portucalensis F11 (cas 19340-14-8)08/02/2019


